KYTX
Kyverna Therapeutics, Inc.
Biotechnology
Market Cap$407M
5Y Perf.-65.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KYTX vs LEGN
Revenue, margins, valuation, and 5-year total return — side by side.
LEGN
Legend Biotech Corporation
Biotechnology
Market Cap$5.28B
5Y Perf.-56.2%
KYTX vs LEGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KYTX | LEGN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $407M | $5.28B |
| Revenue (TTM) | $0.00 | $1.03B |
| Net Income (TTM) | $-161M | $-297M |
| Gross Margin | — | 60.3% |
| Operating Margin | — | -13.2% |
| Forward P/E | — | 118.1x |
| Total Debt | $8M | $414M |
| Cash & Equiv. | $97M | $902M |
KYTX vs LEGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KYTX
LEGN
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| Kyverna Therapeutic… (KYTX) | 100 | 34.2 | -65.8% |
| Legend Biotech Corp… (LEGN) | 100 | 43.8 | -56.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KYTX vs LEGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LEGN leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Kyverna Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
KYTX
Kyverna Therapeutics, Inc.
The Growth Play
KYTX is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- EPS growth -21.2%
- Lower volatility, beta 3.05, Low D/E 3.1%, current ratio 8.61x
- 5.0% margin vs LEGN's -28.8%
Best for: growth exposure and sleep-well-at-night
LEGN
Legend Biotech Corporation
The Income Pick
LEGN carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.77
- -22.8% 10Y total return vs KYTX's -69.0%
- Beta 0.77, current ratio 1.96x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LEGN | 64.5% revenue growth vs KYTX's -91.8% |
| Quality / Margins | KYTX | 5.0% margin vs LEGN's -28.8% |
| Stability / Safety | LEGN | Beta 0.77 vs KYTX's 3.05 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KYTX | +360.4% vs LEGN's -9.2% |
| Efficiency (ROA) | LEGN | -17.6% ROA vs KYTX's -86.0%, ROIC -12.7% vs -106.0% |
KYTX vs LEGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2021
KYTX vs LEGN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLEGNLAGGINGKYTX
KYTXKyverna Therapeutics,…
1leads
LEGNLegend Biotech Corpor…
2leads
6 Total Categories
CATEGORYLEADERvs KYTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KYTX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LEGN6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
LEGN5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KYTX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LEGN and KYTX operate at a comparable scale, with $1.0B and $0 in trailing revenue.
| Metric | KYTXKyverna Therapeut… | LEGNLegend Biotech Co… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $1.0B |
| EBITDAEarnings before interest/tax | -$170M | -$107M |
| Net IncomeAfter-tax profit | -$161M | -$297M |
| Free Cash FlowCash after capex | -$158M | -$231M |
| Gross MarginGross profit ÷ Revenue | — | +60.3% |
| Operating MarginEBIT ÷ Revenue | — | -13.2% |
| Net MarginNet income ÷ Revenue | — | -28.8% |
| FCF MarginFCF ÷ Revenue | — | -22.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +64.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -6.3% | -2.2% |
KYTX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KYTX and LEGN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KYTXKyverna Therapeut… | LEGNLegend Biotech Co… |
|---|---|---|
| Market CapShares × price | $407M | $5.3B |
| Enterprise ValueMkt cap + debt − cash | $319M | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -2.79x | -8.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 118.11x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 5.11x |
| Price / BookPrice ÷ Book value/share | 1.34x | 2.63x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KYTX and LEGN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
LEGN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LEGN delivers a -29.2% return on equity — every $100 of shareholder capital generates $-29 in annual profit, vs $-106 for KYTX. KYTX carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to LEGN's 0.41x. On the Piotroski fundamental quality scale (0–9), KYTX scores 5/9 vs LEGN's 2/9, reflecting solid financial health.
| Metric | KYTXKyverna Therapeut… | LEGNLegend Biotech Co… |
|---|---|---|
| ROE (TTM)Return on equity | -106.0% | -29.2% |
| ROA (TTM)Return on assets | -86.0% | -17.6% |
| ROICReturn on invested capital | -106.0% | -12.7% |
| ROCEReturn on capital employed | -87.4% | -11.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 |
| Debt / EquityFinancial leverage | 0.03x | 0.41x |
| Net DebtTotal debt minus cash | -$88M | -$488M |
| Cash & Equiv.Liquid assets | $97M | $902M |
| Total DebtShort + long-term debt | $8M | $414M |
| Interest CoverageEBIT ÷ Interest expense | -2204.37x | -12.69x |
LEGN leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
LEGN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LEGN five years ago would be worth $9,997 today (with dividends reinvested), compared to $3,100 for KYTX. Over the past 12 months, KYTX leads with a +360.4% total return vs LEGN's -9.2%. The 3-year compound annual growth rate (CAGR) favors LEGN at -25.4% vs KYTX's -32.3% — a key indicator of consistent wealth creation.
| Metric | KYTXKyverna Therapeut… | LEGNLegend Biotech Co… |
|---|---|---|
| YTD ReturnYear-to-date | +6.0% | +32.8% |
| 1-Year ReturnPast 12 months | +360.4% | -9.2% |
| 3-Year ReturnCumulative with dividends | -69.0% | -58.4% |
| 5-Year ReturnCumulative with dividends | -69.0% | -0.0% |
| 10-Year ReturnCumulative with dividends | -69.0% | -22.8% |
| CAGR (3Y)Annualised 3-year return | -32.3% | -25.4% |
LEGN leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KYTX and LEGN each lead in 1 of 2 comparable metrics.
Risk & Volatility
LEGN is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than KYTX's 3.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYTX currently trades 68.0% from its 52-week high vs LEGN's 63.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KYTXKyverna Therapeut… | LEGNLegend Biotech Co… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.05x | 0.77x |
| 52-Week HighHighest price in past year | $13.67 | $45.30 |
| 52-Week LowLowest price in past year | $1.95 | $16.24 |
| % of 52W HighCurrent price vs 52-week peak | +68.0% | +63.1% |
| RSI (14)Momentum oscillator 0–100 | 54.2 | 77.4 |
| Avg Volume (50D)Average daily shares traded | 869K | 1.9M |
Evenly matched — KYTX and LEGN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KYTX as "Buy" and LEGN as "Buy". Consensus price targets imply 251.3% upside for KYTX (target: $33) vs 102.6% for LEGN (target: $58).
| Metric | KYTXKyverna Therapeut… | LEGNLegend Biotech Co… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $32.67 | $57.89 |
| # AnalystsCovering analysts | 4 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
LEGN leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). KYTX leads in 1 (Income & Cash Flow). 2 tied.
Best OverallLegend Biotech Corporation (LEGN)Leads 2 of 6 categories
Loading custom metrics...
KYTX vs LEGN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is KYTX or LEGN a better buy right now?
Analysts rate Kyverna Therapeutics, Inc.
(KYTX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KYTX or LEGN?
Over the past 5 years, Legend Biotech Corporation (LEGN) delivered a total return of -0.
0%, compared to -69. 0% for Kyverna Therapeutics, Inc. (KYTX). Over 10 years, the gap is even starker: LEGN returned -22. 8% versus KYTX's -69. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KYTX or LEGN?
By beta (market sensitivity over 5 years), Legend Biotech Corporation (LEGN) is the lower-risk stock at 0.
77β versus Kyverna Therapeutics, Inc. 's 3. 05β — meaning KYTX is approximately 298% more volatile than LEGN relative to the S&P 500. On balance sheet safety, Kyverna Therapeutics, Inc. (KYTX) carries a lower debt/equity ratio of 3% versus 41% for Legend Biotech Corporation — giving it more financial flexibility in a downturn.
04Which has better profit margins — KYTX or LEGN?
Kyverna Therapeutics, Inc.
(KYTX) is the more profitable company, earning 0. 0% net margin versus -28. 8% for Legend Biotech Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KYTX leads at 0. 0% versus -13. 3% for LEGN. At the gross margin level — before operating expenses — LEGN leads at 60. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is KYTX or LEGN more undervalued right now?
Analyst consensus price targets imply the most upside for KYTX: 251.
3% to $32. 67.
06Which pays a better dividend — KYTX or LEGN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KYTX or LEGN better for a retirement portfolio?
For long-horizon retirement investors, Legend Biotech Corporation (LEGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
77)). Kyverna Therapeutics, Inc. (KYTX) carries a higher beta of 3. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LEGN: -22. 8%, KYTX: -69. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KYTX and LEGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KYTX is a small-cap quality compounder stock; LEGN is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.